Altimmune Inc. (ALT)
Altimmune Statistics
Share Statistics
Altimmune has 77.01M shares outstanding. The number of shares has increased by 8.62% in one year.
| Shares Outstanding | 77.01M |
| Shares Change (YoY) | 8.62% |
| Shares Change (QoQ) | 8.28% |
| Owned by Institutions (%) | 56.91% |
| Shares Floating | 76.21M |
| Failed to Deliver (FTD) Shares | 641 |
| FTD / Avg. Volume | 0.03% |
Short Selling Information
The latest short interest is 22.44M, so 31.55% of the outstanding shares have been sold short.
| Short Interest | 22.44M |
| Short % of Shares Out | 31.55% |
| Short % of Float | 31.64% |
| Short Ratio (days to cover) | 9.02 |
Valuation Ratios
The PE ratio is -5.39 and the forward PE ratio is -3.06. Altimmune's PEG ratio is 0.28.
| PE Ratio | -5.39 |
| Forward PE | -3.06 |
| PS Ratio | 25596.73 |
| Forward PS | 0.7 |
| PB Ratio | 4.14 |
| P/FCF Ratio | -6.41 |
| PEG Ratio | 0.28 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Altimmune.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 13.11, with a Debt / Equity ratio of 0.01.
| Current Ratio | 13.11 |
| Quick Ratio | 13.11 |
| Debt / Equity | 0.01 |
| Debt / EBITDA | -0.02 |
| Debt / FCF | -0.02 |
| Interest Coverage | -11463.56 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $338.98 |
| Profits Per Employee | $-1.61M |
| Employee Count | 59 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -27.68% in the last 52 weeks. The beta is 0.89, so Altimmune's price volatility has been higher than the market average.
| Beta | 0.89 |
| 52-Week Price Change | -27.68% |
| 50-Day Moving Average | 5.3 |
| 200-Day Moving Average | 6.66 |
| Relative Strength Index (RSI) | 54.16 |
| Average Volume (20 Days) | 2.47M |
Income Statement
In the last 12 months, Altimmune had revenue of 20K and earned -95.06M in profits. Earnings per share was -1.34.
| Revenue | 20K |
| Gross Profit | -218K |
| Operating Income | -103.17M |
| Net Income | -95.06M |
| EBITDA | -94.81M |
| EBIT | -95.05M |
| Earnings Per Share (EPS) | -1.34 |
Balance Sheet
The company has 36.93M in cash and 1.68M in debt, giving a net cash position of 35.24M.
| Cash & Cash Equivalents | 36.93M |
| Total Debt | 1.68M |
| Net Cash | 35.24M |
| Retained Earnings | -561.39M |
| Total Assets | 139.31M |
| Working Capital | 126.79M |
Cash Flow
In the last 12 months, operating cash flow was -79.85M and capital expenditures 0, giving a free cash flow of -79.85M.
| Operating Cash Flow | -79.85M |
| Capital Expenditures | 0 |
| Free Cash Flow | -79.85M |
| FCF Per Share | -1.12 |
Margins
Gross margin is -1090%, with operating and profit margins of -515860% and -475295%.
| Gross Margin | -1090% |
| Operating Margin | -515860% |
| Pretax Margin | -475295% |
| Profit Margin | -475295% |
| EBITDA Margin | -474060% |
| EBIT Margin | -515860% |
| FCF Margin | -399240% |
Dividends & Yields
ALT does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for ALT is $24, which is 361.5% higher than the current price. The consensus rating is "Buy".
| Price Target | $24 |
| Price Target Difference | 361.5% |
| Analyst Consensus | Buy |
| Analyst Count | 8 |
Stock Splits
The last stock split was on Sep 14, 2018. It was a backward split with a ratio of 1:30.
| Last Split Date | Sep 14, 2018 |
| Split Type | backward |
| Split Ratio | 1:30 |
Scores
| Altman Z-Score | 8.03 |
| Piotroski F-Score | 2 |